About Rapid Aspirin Desensitization in Coronary Artery Disease Patients. Response

A propósito de la desensibilización rápida al ácido acetilsalicílico de pacientes con cardiopatía isquémica. Respuesta

To the Editor,

We appreciate the interest shown by Morales Martínez de Tejada et al., and we would like to offer some further comments on the points they raised. Regarding the uncertainty as to whether patients had aspirin hypersensitivity, it is true that this cannot be confirmed. Yet this is also the case for most other drug hypersensitivity reactions, for which the history is the main, or even the only, diagnostic tool. However, the protocol developed in collaboration with the allergy service allowed patients to be selected using a carefully taken history. In fact, several patients were excluded due to a low probability of hypersensitivity. It is also true that our study did not include patients with severe reactions to aspirin, but, according to the references consulted, there have been no convincing cases identified of immunoglobulin E-mediated anaphylaxis. The desensitization protocol, which used lysine acetilsalicílico, was performed in the acute care unit, with hemodynamic monitoring and with medical personnel present who were trained to treat the possible complications, given that the effects and pharmacokinetics of lysine acetylsalicylate are not identical to those of aspirin, and that many of the patients had acute coronary syndrome. Our view is that unstable patients are precisely those who could benefit most from aspirin desensitization, as delays in coronary angioplasty could have adverse consequences in such patients. In fact, other hospitals with protocols similar to ours have shown the procedure to be safe, and different published studies have included increasingly greater numbers of patients with acute coronary syndrome. The risks of aspirin desensitization are minimized by a careful history, close collaboration with the allergy service, and monitoring the patients in acute cardiac care units. In addition, since it is impossible to confirm whether patients have true aspirin hypersensitivity, many of those included will have a low level of risk. Thus, early angioplasty can be performed for patients with limited treatment options. Nonetheless, we share Morales Martínez de Tejada’s et al. opinion that more studies on aspirin desensitization are needed if this technique is to be incorporated into everyday clinical practice.

An alternative for acute-phase patients could be the use of glycoprotein IIb/IIIa inhibitors from the outset as part of a dual antiplatelet strategy. However, such an approach is currently not supported by scientific evidence.

Finally, we believe a broad registry is necessary to gather data to enable decisions based on stronger evidence.

Ángel Morales Martínez de Tejada a, b and María del Pilar Abaurrea-Ortiz b

a Unidad Coronaria, Servicio de Cardiología, Hospital Regional Universitario Infanta Cristina, Badajoz, Spain
b Family physician, Centro de Salud de San Juan de Aznalfarache, Sevilla, Spain

*Corresponding author:
E-mail address: hispano0@hotmail.com
Á. Morales Martínez de Tejada.

Available online 18 August 2016

REFERENCES


SEE RELATED ARTICLES:
http://dx.doi.org/10.1016/j.ijicard.2016.04.023
http://dx.doi.org/10.1016/j.ijicard.2016.07.002
http://dx.doi.org/10.1016/j.rec.2016.06.007